

Sub B1
12. (Amended) The method of claim 11, comprising at least one substance having a lactone structure with a carbonyl moiety.

13. (Amended) The method of claim 11, wherein at least one substance is coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone, isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl (racumin), (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin and related flavones, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, miconazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, analogs thereof and derivatives thereof.

AS Sub B1
16. (Amended) The method of any one of claims 11-15, wherein the condition is dependent or non-dependent tobacco use.

Sub B1
21. (Amended) A pharmaceutical composition comprising an amount effective to regulate the metabolism of nicotine to cotinine wherein at least one substance selectively inhibits CYP2A6 and at least one substance inhibits CYP2B6.

22. (Amended) The composition of claim 21, comprising at least one substance having a lactone structure with a carbonyl moiety.

23. (Amended) The composition of claim 21, wherein at least one substance is coumarin, furanocoumarin, methoxsalen, imperatorin, psoralen, α -naphthoflavone, isopimpinellin, β -naphthoflavone, bergapten, sphondin, coumatetralyl (racumin), (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidim-4-one, naringenin and related flavones, diethyldithiocarbamate, N-nitrosodialkylamine, nitropyrene, menadione, imidazole antimycotics, miconazole, clotrimazole, pilocarpine, hexamethylphosphoramide, 4-methylnitrosamine-3-pyridyl-1-butanol, aflatoxin B, analogs thereof and derivatives thereof.

~~30. (Amended) The method of claim 25, wherein the condition is dependent or non-dependent tobacco use.~~

~~38. (Amended) A method for treating a condition requiring regulation of nicotine metabolism to cotinine in an individual comprising administering to said individual: (a) an effective amount of a first substance which selectively inhibits CYP2A6; and (b) an effective amount of a second substance which is capable of inhibiting the metabolism of the first substance.~~

~~39. (New) The method of claim 11, wherein the substance is methoxsalen or derivatives thereof.~~

~~40. (New) The method of claim 16, wherein the substance is methoxsalen or derivatives thereof.~~

~~41. (New) The method of claim 38, wherein at least one of said substances is methoxsalen or derivatives thereof.~~

~~42. (New) A method for reducing nicotine intake comprising administering to the subject in need of reduced nicotine intake a substance which selectively inhibits CYP2A6.~~

~~43. (New) The method of claim 42 comprising another substance capable of regulating inhibition of the first substance.~~

~~44. (New) The method of claim 42, wherein said substance delays metabolism of nicotine to cotinine.~~